Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

Cited by (1,003)

Items 401–500 of 1,003

1. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches
   Elaine S Tan, İbrahim Halil Şahin · 2021 · Expert Review of Gastroenterology & Hepatology
2. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
   Raquel Aguiar‐Ibáñez, Chloë Hardern, Frank van Hees, Dawn Lee, Anubhav Patel, Nitika Chhabra, Gargi Baluni, Mayur Mohan Amonkar, Yizhen Lai, Ruifeng Xu et al. · 2022 · Journal of Medical Economics
3. Immunotherapy-induced Hepatotoxicity: A Review
   Teresa Da Cunha, George Y. Wu, Haleh Vaziri · 2022 · Journal of Clinical and Translational Hepatology
4. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
   Lindor Qunaj, Michael S. May, Alfred I. Neugut, Benjamin O. Herzberg · 2023 · Frontiers in Oncology
5. Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade
   Jie Mei, Yun Cai, Rui Xu, Qing Li, Jiahui Chu, Zhiwen Luo, Yaying Sun, Yuxin Shi, Junying Xu, Di Li et al. · 2024 · 癌症：英文版
6. Deep learning for dual detection of microsatellite instability and POLE mutations in colorectal cancer histopathology
   Marco Gustav, Nic Gabriel Reitsam, Zunamys Itzell Carrero, Chiara Maria Lavinia Loeffler, Marko van Treeck, Tanwei Yuan, Nicholas Paul West, Philip Quirke, Titus J. Brinker, Hermann Brenner et al. · 2024 · npj Precision Oncology
7. An update on applications of digital pathology: primary diagnosis; telepathology, education and research
   Shamail Zia, Isil Z. Yildiz-Aktas, Fazail Zia, Anil Vasdev Parwani · 2025 · Diagnostic Pathology
8. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells
   Ce Luo, Rui Zhang, Rui Guo, Lijian Wu, Teng Xue, Yufeng He, Yiteng Jin, Yanping Zhao, Zongxu Zhang, Peng Zhang et al. · 2025 · Immunity
9. Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
   Fausto Petrelli, Anna Maria Morelli, Andrea Luciani, Antonio Ghidini, Cinzia Solinas · 2021 · Targeted Oncology
10. MSI colorectal cancer, all you need to know
    Clémence Flecchia, Aziz Zaanan, Widad Lahlou, Debora Basile, Chloé Broudin, Claire Gallois, Lorenzo Pilla, Mehdi Karoui, Gilles Manceau, Julien Taı̈eb · 2022 · Clinics and Research in Hepatology and Gastroenterology
11. Targeting KRASG12C in colorectal cancer: the beginning of a new era
    Davide Ciardiello, Brigida Anna Maiorano, Erika Martinelli · 2022 · ESMO Open
12. Fibroblast activation protein identifies consensus molecular subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging
    Strating, Esther, Wassenaar, Emma, Verhagen, Mathijs, Rauwerdink, Paulien, van Schelven, Susanne, de Hingh, Ignace, Rinkes, Inne Borel, Boerma, Djamila, Witkamp, Arjen, Lacle, Miangela et al. · 2022 · British Journal of Cancer
13. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
    Alessandra Boccaccino, Beatrice Borelli, Rossana Intini, Maria Antista, Maria Bensi, Daniele Rossini, Alessandro Passardi, Stefano Tamberi, Riccardo Giampieri, Lorenzo Antonuzzo et al. · 2022 · ESMO Open
14. Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects
    Maximilian Boesch, Lena Horvath, Florent Baty, Andreas Pircher, Dominik Georg Friedrich Wolf, Stephan Spahn, Ravid Straussman, Herbert Tilg, Martin Hugo Brutsche · 2022 · Journal for ImmunoTherapy of Cancer
15. Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study
    Erika Martinelli, Chiara Cremolini, Thibault Mazard, Joana Vidal, Isabel Virchow, David Tougeron, Pieter‐Jan Cuyle, Benoist Chibaudel, Stefano Chong Hun Kim, Ismael Ghanem et al. · 2022 · ESMO Open
16. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer
    Joanna El Hajj, Sarah Reddy, Nilesh Verma, Emina H. Huang, Syed Mohammad Ali Kazmi · 2023 · Journal of Gastrointestinal Cancer
17. Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
    Claire Gallois, Matteo Landi, Julien Taı̈eb, Marine Sroussi, Bahar Saberzadeh-Ardestani, Antoine Cazelles, Sara Lonardi, Francesca Bergamo, Rossana Intini, Giulia Maddalena et al. · 2023 · Clinical Cancer Research
18. Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
    Rachel S. Goodman, Seungyeon Jung, Justin Micah Balko, Douglas Buckner Johnson · 2023 · Immunological Reviews
19. Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
    Yang Liu, Jennifer Altreuter, Sudheshna Bodapati, Simona Cristea, Cheryl J. Wong, Catherine J. Wu, Franziska Michor · 2023 · Cell Genomics
20. Boosting Ferroptosis and immunotherapy for Colorectal Cancer by Lactate‐Related Metabolic Reprogramming
    Zhenhao Li, Shan He, Lei Xie, Guoning Zeng, Jiehao Huang, Huaiming Wang, Hongwu Chen, Tingting Deng, Yubin Xia, Cong Huang et al. · 2024 · Advanced Functional Materials
21. The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors
    Lorena Incorvaia, Tancredi Didier Bazan Russo, Valerio Gristina, Alessandro Perez, Chiara Brando, Clarissa Mujacic, Emilia Di Giovanni, Marco Bono, Silvia Contino, Carla Ferrante Bannera et al. · 2024 · npj Precision Oncology
22. PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer
    Xiaozhuo Ran, Bell Xi Wu, Venkatasubramanian Vidhyasagar, Lifang Song, Xu Zhang, Reese Jalal Ladak, Mona Teng, Wail Ba-Alawi, Vivek Philip, Housheng Hansen He et al. · 2025 · Nature Communications
23. Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors
    Joy A. Awosika, James L. Gulley, Danielle M. Pastor · 2025 · International Journal of Molecular Sciences
24. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
    Chongkai Wang, Marwan Fakih · 2021 · Expert Opinion on Biological Therapy
25. Perspectives on Immunotherapy of Metastatic Colorectal Cancer
    Yongjiu Dai, Wenhu Zhao, Lei Yue, Xinzheng Dai, Dawei Rong, Fan Wu, Jian Gu, Xiaofeng Qian · 2021 · Frontiers in Oncology
26. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?—Case series and review of the literature
    Hiroki Osumi, Loredana Vecchione, Ulrich Keilholz, Claudia Vollbrecht, Annabel Helga Sophie Alig, Jobst Christian von Einem, Arndt Stahler, Jana Käthe Striefler, Annika Kurreck, Andreas Jay Kind et al. · 2021 · European Journal of Cancer
27. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
    Daniele Fanale, Lidia Rita Corsini, Raimondo Scalia, Chiara Brando, Alessandra Cucinella, Giorgio Madonia, Alessandra Dimino, Clarissa Filorizzo, Nadia Barraco, Marco Bono et al. · 2022 · Critical Reviews in Oncology/Hematology
28. Pan-Cancer Analyses Confirmed the Ferroptosis-Related Gene SLC7A11 as a Prognostic Biomarker for Cancer
    Yi Lin, Yubing Dong, Wanyu Liu, Xingyun Fan, Ying Sun · 2022 · International Journal of General Medicine
29. Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
    Michael Kuske, Maximilian Haist, Thomas Jung, Stephan Grabbe, Matthias Bros · 2022 · Cancers
30. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives
    María Carmen Riesco Martínez, Andrea Modrego, Paula Espinosa-Olarte, Anna La Salvia, Rocio García‐Carbonero · 2022 · Current Treatment Options in Oncology
31. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
    Napolitano, Stefania, Martini, Giulia, Ciardiello, Davide, Di Maio, Massimo, Normanno, Nicola, Avallone, Antonio, Martinelli, Erika, Maiello, Evaristo, Troiani, Teresa, Ciardiello, Fortunato · 2022 · Frontiers in Oncology
32. Testing for deficient mismatch repair and microsatellite instability
    Josef Rüschoff, Hans‐Ulrich Schildhaus, Jan Hendrik Rüschoff, Korinna Jöhrens, Tina Bocker Edmonston, Wolfgang Dietmaier, Hendrik Bläker, Gustavo Bruno Baretton, David A. Horst, Manfred Dietel et al. · 2023 · Die Pathologie
33. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
    Shogo Takei, Yosuke Tanaka, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima et al. · 2024 · Journal for ImmunoTherapy of Cancer
34. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model
    Kun Chan Zheng, Youlong Hai, Hongqi Chen, Yukun Zhang, Xiaoyong Hu, Kai Ni · 2024 · Journal of Translational Medicine
35. Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer
    Wenxuan Fan, Fei Su, Yan Zhang, Xiaoling Zhang, Yunyi Du, Yangjun Gao, Weiling Li, Wenqing Hu, Jun Zhao · 2024 · Biomarker Research
36. A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice
    Yixuan Liu, Ying Xie, Yuling Chen, Jia‐Lun Duan, Chun‐Jie Bao, Jinling Wang, Hexuan Feng, Mengjie Wang, Yuxin Ren, Peishan Li et al. · 2025 · Nature Communications
37. Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications
    De-Ning Ma, Xinyi Gao, Li Wang, Huan Yin, Long-Hai Feng, Yuping Zhu · 2025 · Biomarker Research
38. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?
    Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash, Emil Lou · 2021 · Molecular Therapy — Oncolytics
39. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
    Yanhao Liu, Yan Xu, Xi Cheng, Yaru Lin, Shu Jiang, Haiming Yu, Zhen Zhang, Linlin Lu, Xiaotao Zhang · 2022 · Frontiers in Immunology
40. Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer
    Yao Chen, Bingjun Bai, Kangkang Ying, Hongming Pan, Binbin Xie · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
41. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers
    Xiaoyu Liu, Xu Xu, Zhuozhuo Wu, Qungang Shan, Ziyin Wang, Zhiyuan Wu, Xiaoyi Ding, Wei Huang, Zhongmin Wang · 2022 · Frontiers in Immunology
42. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
    Ronan Joseph Kelly, Katherine M. Bever, Joseph Chao, Kristen K. Ciombor, Cathy Eng, Marwan Fakih, Lipika Goyal, Joleen Marie Hubbard, Renuka V. Iyer, Holly Kemberling et al. · 2023 · Journal for ImmunoTherapy of Cancer
43. A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research
    G. Emerens Wensink, Marinde J. G. Bond, Emre Küçükköse, Anne Maria May, Geraldine R. Vink, Miriam Koopman, Onno Kranenburg, Jeanine M.L. Roodhart · 2021 · Cancer Treatment Reviews
44. Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases
    Yangsong He, Yanan Han, Ahui Fan, Danxiu Li, Boda Wang, Kun Ji, Xin Wang, Xiaodi Zhao, Yuanyuan Lu · 2022 · Journal of Translational Medicine
45. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
    Sofia Edin, Björn Gylling, Xingru Li, Åsa Stenberg, Anna Löfgren‐Burström, Carl Zingmark, Bethany R. Van Guelpen, Ingrid Ljuslinder, Agnes Ling, Richard Palmqvist · 2023 · British Journal of Cancer
46. Predictors of response to immunotherapy in colorectal cancer
    Jaime González‐Montero, Carlos I Rojas, Mauricio Burotto · 2024 · The Oncologist
47. Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
    Marwa Abdel Hamid, Lorenz Michael Pammer, Theresa Lentner, Bernhard Doleschal, Rebecca Gruber, Florian Kocher, Elisabeth Gasser, Anna Jöbstl, Andreas Seeber, Arno Amann · 2024 · Current Oncology Reports
48. Therapeutic targeting of mismatch repair-deficient cancers
    Paul M. Johannet, Benoı̂t Rousseau, Carol A Aghajanian, Michael Bonner Foote, Luis Alberto Diaz · 2025 · Nature Reviews Clinical Oncology
49. Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
    Pedro Batista Tan, Yara L. Verschoor, José G. van den Berg, Sara Balduzzi, Niels F.M. Kok, Marieke E. Ijsselsteijn, Kat Moore, Adham Adel Jurdi, Antony Tin, Paulien Kaptein et al. · 2025 · Nature
50. Current status and future perspective of immune checkpoint inhibitors in colorectal cancer
    Cong Zhou, Xiaojiao Cheng, Shuiping Tu · 2021 · Cancer Letters
51. Personalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
    Lifeng Hu, Huanrong Lan, Dong Huang, Xuemin Li, Ketao Jin · 2021 · Frontiers in Oncology
52. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
    Marta Español‐Rego, Carlos Fernández-Martos, Elena Élez, Carles Foguet, Leire Pedrosa, Núria Rodríguez, Ana Ruiz‐Casado, Estela Pineda, Joan Cid, Raquel Cabezón et al. · 2022 · Cancer Immunology Immunotherapy
53. HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
    Mariia D. Ivanova, Konstantinos Venetis, Elena Guerini‐Rocco, Luca Bottiglieri, Mauro Giuseppe Mastropasqua, Ornella Garrone, Nicola Fusco, Michele Ghidini · 2022 · Life
54. Deep Learning Algorithm‑Based MRI Radiomics and Pathomics for Predicting Microsatellite Instability Status in Rectal Cancer: A Multicenter Study
    Xiuzhen Yao, Shuitang Deng, Xiaoyu Han, Danjiang Huang, Zhengyu Cao, Xiaoxiang Ning, Weiqun Ao · 2024 · Academic Radiology
55. p53 in colorectal cancer: from a master player to a privileged therapy target
    Sicheng Yan, Fuyuan Zhan, Yuxuan He, Yuehong Zhu, Zhihong Ma · 2025 · Journal of Translational Medicine
56. Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer
    Carine El Sissy, Amos Kirilovsky, Guy Zeitoun, Florence Marliot, Nacilla Haicheur, Christine Lagorce, Jérôme Galon, Franck Pagès · 2021 · Cancers
57. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
    Matthew K. Stein, Oluchukwu Oluoha, Kruti Patel, Ari M. Vanderwalde · 2021 · Journal of Personalized Medicine
58. Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
    Alessio Amatu, Gianluca Mauri, Federica Tosi, Katia Bruna Bencardino, Erica Francesca Bonazzina, Viviana Gori, Lorenzo Ruggieri, Sabrina Arena, Alberto Bardelli, Silvia Marsoni et al. · 2022 · Cancers
59. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
    Qingqing Xie, Pengfei Zhang, Yuanyuan Wang, Wuxuan Mei, Changchun Zeng · 2022 · Frontiers in Oncology
60. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
    Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, Kehe Chen, Peiguo Cao, Jianjun Xiao et al. · 2022 · British Journal of Cancer
61. Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes
    Nic Gabriel Reitsam, Bruno Märkl, Sebastian Dintner, Johanna Waidhauser, Dmytro Vlasenko, Bianca Grosser · 2022 · Frontiers in Oncology
62. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability—Lessons from Colorectal Cancer
    Luana Greco, Federica Rubbino, Arianna Dal Buono, Luigi Laghi · 2023 · Genes
63. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy
    Mingchao Wang, Xiaojuan Ran, Wendy Leung, Ajinkya S. Kawale, Sneha Saxena, Jian Ouyang, Parasvi S. Patel, Yuting Dong, Tao Yin, Jian Shu et al. · 2023 · Genes & Development
64. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
    Qianyu Wang, Xiaofei Shen, Gang Chen, Junfeng Du · 2023 · International Journal of Cancer
65. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting
    Bahar Saberzadeh-Ardestani, Jeremy Clifton Jones, Robert R. McWilliams, David Tougeron, Thorvardur Ragnar Halfdanarson, Rosine Guimbaud, Joleen Marie Hubbard, Clémence Flecchia, Qian Shi, Emily Linda Alouani et al. · 2023 · European Journal of Cancer
66. Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
    Huixin Zhang, Lysa Houadj, Kevin Yang Wu, Simon D. Tran · 2024 · Diagnostics
67. Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance
    Annachiara Esposito, A. Agostini, Giuseppe Quero, Geny Piro, Lorenzo Priori, Alessia Caggiano, Giulia Scaglione, Alessandra Battaglia, Maria Alessandra Calegari, Lisa Salvatore et al. · 2024 · Cell Death and Disease
68. Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes
    Dmitrii Shek, L. G. Akhuba, Matteo Salvatore Carlino, Adnan M. Nagrial, Tania Moujaber, Scott A. Read, Bo Gao, Golo Ahlenstiel · 2021 · Cancers
69. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer
    Anai N. Kothari, Michael Geoffrey White, Oliver Peacock, Harmeet Kaur, Sarah M. Palmquist, Nancy You, Melissa W. Taggart, Usama I. Salem, Michael James Overman, Scott Kopetz et al. · 2022 · British journal of surgery
70. Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity
    Trevor S. Anderson, Amanda L. McCormick, Savanna L Piersall, Izuchukwu F. Okpalanwaka, Devin B. Lowe · 2022 · Seminars in Cancer Biology
71. Tumor redox microenvironment modulating composite hydrogels for enhanced sonodynamic therapy of colorectal cancer
    Weikai Chen, Chenxi Zhang, Dagui Chen, Yinghua Li, Shunli Wu, Can Xu, Li Su, Qin Zhang · 2022 · Journal of Materials Chemistry B
72. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
    Jan Budczies, Klaus Kluck, Susanne Beck, Iordanis Ourailidis, Michael Allgäuer, Michael Menzel, Daniel N. Kazdal, Lukas Perkhofer, Alexander Kleger, Peter Schirmacher et al. · 2022 · The Journal of Pathology Clinical Research
73. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016
    Chan Shen, Daniel Tannenbaum, Robert G. Horn, Jane Elizabeth Rogers, Cathy Eng, Shouhao Zhou, Benny Johnson, Scott Kopetz, Van Karlyle Morris, Michael James Overman et al. · 2022 · JAMA Network Open
74. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
    Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni et al. · 2023 · Current Oncology
75. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
    Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Masato Yoneda · 2023 · Journal of Clinical and Translational Hepatology
76. Hereditary colorectal, gastric, and pancreatic cancer: comprehensive review
    Toni T. Seppälä, Richard A. Burkhart, Bryson W. Katona · 2023 · BJS Open
77. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future
    İbrahim Halil Şahin, Janie Yue Zhang, Turçin Saridogan, Vikram C. Gorantla, John Rhree, Monica Khunger Malhotra, Roby Antony Thomas, Dennis J. Hsu, Anwaar Saeed · 2023 · JCO Oncology Practice
78. Oligometastatic Colorectal Cancer: A Review of Definitions and Patient Selection for Local Therapies
    Miller, Eric D., Hitchcock, Kathryn E., Romesser, Paul B. · 2023 · Journal of Gastrointestinal Cancer
79. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
    Jordan W. Conway, Jorja Braden, James S. Wilmott, Richard A. Scolyer, Georgina Venetia Long, Inês Pires da Silva · 2022 · Frontiers in Immunology
80. Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease
    Josef Leibold, Kaloyan M. Tsanov, Corina Amor, Yu-Jui Ho, Francisco J. Sánchez Rivera, Judith Feucht, Timour Baslan, Hsuan-An Chen, Sha Tian, Janelle M. Simon et al. · 2024 · Nature Cancer
81. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
    Anne Hansen Ree, Jūratė Šaltytė Benth, Hanne Mari Hamre, Christian Kersten, Eva Hofsli, Marianne G. Guren, Halfdan Sørbye, Christin Johansen, Anne Negård, Tonje Bjørnetrø et al. · 2024 · British Journal of Cancer
82. ZEB1-mediated fibroblast polarization controls inflammation and sensitivity to immunotherapy in colorectal cancer
    Constantin Menche, Harald Schuhwerk, Isabell Armstark, Pooja Gupta, Kathrin Fuchs, Ruthger van Roey, Mohammed H. Mosa, Anne Hartebrodt, Yussuf Hajjaj, Ana Clavel Ezquerra et al. · 2024 · EMBO Reports
83. Recent advances and challenges in colorectal cancer: From molecular research to treatment
    Gaoxiu Qi, Ruixia Zhao, Chen Gao, Zeliang Ma, Shang Wang, Jing Xu · 2025 · World Journal of Gastroenterology
84. Spatially resolved C1QC+ macrophage-CD4+ T cell niche in colorectal cancer microenvironment: implications for immunotherapy response
    Hangyu Zhang, Libing Hong, Zhen Dong, Xin Shan, Bo Lin, Jinlin Cheng, Weihong Tian, Бин Ли, Jing Wang, Xiaoyan Liu et al. · 2025 · Cell Discovery
85. Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer
    Van Karlyle Morris, Christine Megerdichian Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal, Kangyu Lin, Kanwal P. S. Raghav, Robert A. Wolff, Arvind N. Dasari et al. · 2025 · Cancer Cell
86. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
    Giovanni Fucà, Francesca Corti, Margherita Ambrosini, Rossana Intini, Massimiliano Salati, Elisabetta Fenocchio, Paolo Manca, Chiara Manai, Francesca Daniel, Alessandra Raimondi et al. · 2021 · Journal for ImmunoTherapy of Cancer
87. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
    Carlotta Antoniotti, Wolfgang Michael Korn, Federica Marmorino, Daniele Rossini, Sara Lonardi, Gianluca Masi, Giovanni Randon, Veronica Conca, Alessandra Boccaccino, Gianluca Tomasello et al. · 2021 · European Journal of Cancer
88. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives
    Robert John Walsh, David S.P. Tan · 2021 · Journal of Clinical Medicine
89. Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer
    Dorothea Plundrich, Sophia Chikhladze, Stefan Fichtner‐Feigl, Reinhild Feuerstein, Priscilla S. Briquez · 2022 · International Journal of Molecular Sciences
90. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer
    Andreas Seeber, Francesca Battaglin, Kai Zimmer, Florian Kocher, Yasmine Baca, Joanne Xiu, Gilbert Spizzo, Veronica Novotny‐Diermayr, Dietmar Rieder, Alberto Puccini et al. · 2022 · Clinical Cancer Research
91. Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
    Branka Petričević, Julijan Kabiljo, Rebecca Zirnbauer, Henning Walczak, Johannes Laengle, Michael M. Bergmann · 2022 · Seminars in Cancer Biology
92. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer
    Giacomo Mazzoli, Romain Cohen, Sara Lonardi, Francesca Corti, Elena Élez, Marwan Fakih, Priya Jayachandran, Raphaël Colle, Aakash Tushar Shah, Massimiliano Salati et al. · 2022 · European Journal of Cancer
93. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
    Deniz Can Güven, Taha Koray Şahin, Enes Erul, İbrahim Yahya Çakır, Enes Üçgül, Hasan Çağrı Yıldırım, Oktay Halit Aktepe, Mustafa Erman, Saadettin Kılıçkap, Sercan Aksoy et al. · 2022 · Journal of Clinical Medicine
94. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
    Mathieu J. F. Crupi, Zaid Taha, Thijs J. A. Janssen, Julia Petryk, Stephen Boulton, Nouf Alluqmani, Anna Jirovec, Omar Kassas, S. Khan, Sydney Vallati et al. · 2022 · Frontiers in Immunology
95. Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer
    Zhuo, Na, Liu, Chang, Zhang, Qi, Li, Jian, Zhang, Xiaotian, Gong, Jifang, Lu, Ming, Peng, Zhi, Zhou, Jun, Wang, Xicheng et al. · 2022 · JAMA Network Open
96. The role of microbiomes in gastrointestinal cancers: new insights
    Aref Yarahmadi, Hamed Afkhami · 2024 · Frontiers in Oncology
97. Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration
    Fenglian He, Zhongen Wu, Chenglong Liu, Yuanyuan Zhu, Yan Zhou, Enming Tian, Rina Rosin‐Arbesfeld, Dehua Yang, Ming‐Wei Wang, Di Zhu · 2024 · Signal Transduction and Targeted Therapy
98. The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates
    Liuyue Kan, Yingyan Yu, Yaxue Wang, Lei Shi, Tingyuan Fan, Hui Chen, Chuanli Ren · 2025 · Molecular Cancer
99. Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study
    Feng Wang, Gong Chen, Meng Qiu, Jinfeng Ma, Xianwei Mo, Haiyi Liu, Yongqiang Li, Peirong Ding, Xiangbin Wan, Yingbin Hu et al. · 2025 · Cancer Cell
100. Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer
     Frank A. Sinicrope, Fang‐Shu Ou, Dirk Arnold, Walter R. Peters, Robert J. Behrens, Christopher Hanyoung Lieu, Khalid Matin, Deirdre Jill Cohen, Samara L. Poplack Potter, Andrew B. Nixon et al. · 2026 · New England Journal of Medicine